CIK 0001664710 · Non-accelerated filer<br>Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 811173868
- Phone
- 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $10,270
- in 1 filing
- Open-market sales, last 90 days
- $101,136
- in 4 filings, $6K under 10b5-1 plans
Net −$90,866. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 78 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-09 | ADAR1 Capital Management, LLC 10% owner | Purchase | +18,560 | $9.40 | $174K | 3,493,404 |
| 2025-04-09 | ADAR1 Capital Management, LLC 10% owner | Purchase | +16,365 | $9.40 | $154K | 743,558 |
| 2025-04-09 | ADAR1 Capital Management, LLC 10% owner | Purchase | +325,000 | $9.86 | $3.2M | 3,818,404 |
| 2025-04-09 | ADAR1 Capital Management, LLC 10% owner | Purchase | +500,000 | $10.33 | $5.2M | 4,318,404 |
| 2025-04-09 | ADAR1 Capital Management, LLC 10% owner | Purchase | +74,333 | $10.33 | $768K | 4,392,737 |
| 2025-04-09 | ADAR1 Capital Management, LLC 10% owner | Other disposition · Cash-Settled Total Return Swaps | −325,000 | 624,333 | ||
| 2025-04-09 | ADAR1 Capital Management, LLC 10% owner | Other disposition · Cash-Settled Total Return Swaps | −500,000 | 124,333 | ||
| 2025-04-09 | ADAR1 Capital Management, LLC 10% owner | Other disposition · Cash Settled Total Return Swaps | −74,333 | 50,000 | ||
| 2025-04-04 | Seehra Jasbir CHIEF EXECUTIVE OFFICER | Option exercise | +49,367 | $0.30 | $15K | 302,223 |
| 2025-04-04 | Seehra Jasbir CHIEF EXECUTIVE OFFICER | Option exercise · Employee Stock Option (right to buy) | −49,367 | 252,444 | ||
| 2025-02-18 | CHYUNG YUNG H. Chief Medical Officer | Grant or award | +44,000 | 44,000 | ||
| 2025-02-18 | Regnante Keith CHIEF FINANCIAL OFFICER | Grant or award | +44,000 | 44,000 | ||
| 2025-02-18 | Rovaldi Christopher Chief Operating Officer | Grant or award | +60,000 | 60,000 | ||
| 2024-11-08 | CHYUNG YUNG H. Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2024-08-13 | GORDON CARL L Director | Sale | −220,600 | $44.01 | $9.7M | 899,212 |
| 2024-08-13 | GORDON CARL L Director | Sale | −29,400 | $44.01 | $1.3M | 119,522 |
| 2024-08-13 | ORBIMED ADVISORS LLC Director | Sale | −220,600 | $44.01 | $9.7M | 899,212 |
| 2024-08-13 | ORBIMED ADVISORS LLC Director | Sale | −29,400 | $44.01 | $1.3M | 119,522 |
| 2024-06-03 | BIENAIME JEAN JACQUES Director | Grant or award · Stock Option (right to buy) | +17,600 | 17,600 | ||
| 2024-05-30 | Seth Alpna Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 |
Page 5 of 9 · 173 trades